Analysis of the Anticancer Activity of Curcuminoids, Thiotryptophan and 4-phenoxyphenol Derivatives

Overview

Journal Oncol Lett

Specialty Oncology

Date 2013 Dec 19

PMID 24348813

Citations 14

Authors

Shireen Parsai

Rick Keck

Ewa Skrzypczak-Jankun

Jerzy Jankun

Affiliations

Soon will be listed here.

Abstract

Curcumin, a non-nutritive yellow pigment derived from the rhizome of (turmeric), is considered to be an established nutraceutical with anticancer activity. Turmeric contains three principal components, curcumin, demethoxycurcumin and bisdemethoxycurcumin, of which curcumin is most abundant and potent. The concurrence of a high consumption of turmeric and a low incidence of prostate cancer in Asian countries may suggest a role for curcumin in chemoprevention. Curcumin has been identified to exhibit anti-inflammatory, anti-oxidative and anticarcinogenic properties. Since the compound does not exhibit side effects, curcumin has been designated for several clinical trials as a treatment for human cancers. The pro-apototic, antioxidant and anti-inflammatory characteristics of curcumin are implicated in its anticancer activity, yet the mechanism of action of curcumin remains unknown. To achieve an effective pharmacological outcome, curcumin must reach and sustain appropriate levels at the site of action. However, the main disadvantage of curcumin is its high metabolic instability and poor aqueous solubility that limits its systemic bioavailability. To overcome this difficulty, the present study tested the anticancer activity of new curcumin-like compounds (E21cH and Q012095H). Also, the use of new medicaments requires an understanding of their pharmacokinetic profiles and targets. Thus, molecular modeling methods were used to identify the targets of curcumin and curcumin-like compounds compared with other anticancer drugs (Q012138 and Q012169AT), which were used as the controls. The present study identified several enzymes that are targeted by curcumin, aldo-keto reductase family 1 member B10 (AKR1B10), serine/threonine-protein kinase, protein kinase C, matrix metalloproteinase (MMP), cyclooxygenase and epidermal growth factor receptor, which were tested as targets for these anticancer chemicals. All the examined small compounds demonstrated anticancer activity in the experiments and may impact cancer cells by acting on AKR1B10, MMP-9 and their targets.

Citing Articles

Curcuminoids as Anticancer Drugs: Pleiotropic Effects, Potential for Metabolic Reprogramming and Prospects for the Future.

Pouliquen D, Gall Troselj K, Anto R Pharmaceutics. 2023; 15(6).

PMID: 37376060 PMC: 10303184. DOI: 10.3390/pharmaceutics15061612.

The Cytotoxicity of Carbon Nanotubes and Hydroxyapatite, and Graphene and Hydroxyapatite Nanocomposites against Breast Cancer Cells.

Nguyen T, Maniyar A, Sarkar M, Sarkar T, Neelgund G Nanomaterials (Basel). 2023; 13(3).

PMID: 36770518 PMC: 9919526. DOI: 10.3390/nano13030556.

diTFPP, a Phenoxyphenol, Sensitizes Hepatocellular Carcinoma Cells to C-Ceramide-Induced Autophagic Stress by Increasing Oxidative Stress and ER Stress Accompanied by LAMP2 Hypoglycosylation.

Chiu C, Chen Y, Bow Y, Chen J, Liu W, Huang J Cancers (Basel). 2022; 14(10).

PMID: 35626132 PMC: 9139631. DOI: 10.3390/cancers14102528.

Cytotoxicity of synthetic derivatives against breast cancer and multi-drug resistant breast cancer cell lines: a literature-based perspective study.

Sharmin S, Rahaman M, Martorell M, Sastre-Serra J, Sharifi-Rad J, Butnariu M Cancer Cell Int. 2021; 21(1):612.

PMID: 34801046 PMC: 8606078. DOI: 10.1186/s12935-021-02309-9.

Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds.

Chavda V, Ertas Y, Walhekar V, Modh D, Doshi A, Shah N Front Pharmacol. 2021; 12:702611.

PMID: 34483905 PMC: 8416109. DOI: 10.3389/fphar.2021.702611.

References

Cuendet M, Pezzuto J . The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact. 2001; 17(1-4):109-57. DOI: 10.1515/dmdi.2000.17.1-4.109. View

Gafner S, Lee S, Cuendet M, Barthelemy S, Vergnes L, Labidalle S . Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry. 2004; 65(21):2849-59. DOI: 10.1016/j.phytochem.2004.08.008. View

Park W, Amin A, Chen Z, Shin D . New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013; 6(5):387-400. PMC: 3693758. DOI: 10.1158/1940-6207.CAPR-12-0410. View

Deters M, Hutten H, Kaever V . Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin. Phytomedicine. 2012; 20(2):120-3. DOI: 10.1016/j.phymed.2012.09.018. View

Tochowicz A, Maskos K, Huber R, Oltenfreiter R, Dive V, Yiotakis A . Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol. 2007; 371(4):989-1006. DOI: 10.1016/j.jmb.2007.05.068. View

Xu Y, Cao Y, Ma H, Li H, Ao G . Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity. Bioorg Med Chem. 2012; 21(2):388-94. DOI: 10.1016/j.bmc.2012.11.031. View

Jankun J, Aleem A, Selman S, Basrur V, Skrzypczak-Jankun E . VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form. Int J Mol Med. 2008; 23(1):57-63. View

Arcangeli S, Pinzi V, Arcangeli G . Epidemiology of prostate cancer and treatment remarks. World J Radiol. 2012; 4(6):241-6. PMC: 3391668. DOI: 10.4329/wjr.v4.i6.241. View

Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J . Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011; 30(1):83-95. DOI: 10.1007/s10555-011-9281-4. View

10.

Dorai T, Gehani N, Katz A . Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis. 2002; 3(2):84-93. DOI: 10.1038/sj.pcan.4500399. View

11.

Conboy L, Foley A, OBoyle N, Lawlor M, Gallagher H, Murphy K . Curcumin-induced degradation of PKC delta is associated with enhanced dentate NCAM PSA expression and spatial learning in adult and aged Wistar rats. Biochem Pharmacol. 2009; 77(7):1254-65. DOI: 10.1016/j.bcp.2008.12.011. View

12.

Benes C, Wu N, Elia A, Dharia T, Cantley L, Soltoff S . The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005; 121(2):271-80. DOI: 10.1016/j.cell.2005.02.019. View

13.

Iorga B, Herlem D, Barre E, Guillou C . Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach. J Mol Model. 2005; 12(3):366-72. DOI: 10.1007/s00894-005-0057-z. View

14.

Gallego O, Ruiz F, Ardevol A, Dominguez M, Alvarez R, de Lera A . Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007; 104(52):20764-9. PMC: 2410076. DOI: 10.1073/pnas.0705659105. View

15.

Seeliger D, de Groot B . Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010; 24(5):417-22. PMC: 2881210. DOI: 10.1007/s10822-010-9352-6. View

16.

Tokunaga C, Yoshino K, Yonezawa K . mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun. 2003; 313(2):443-6. DOI: 10.1016/j.bbrc.2003.07.019. View

17.

Zingg J, Hasan S, Meydani M . Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors. 2013; 39(1):101-21. DOI: 10.1002/biof.1072. View

18.

Agrawal D, Mishra P . Curcumin and its analogues: potential anticancer agents. Med Res Rev. 2009; 30(5):818-60. DOI: 10.1002/med.20188. View

19.

Liu K, Bagrodia S, Bailey S, Cheng H, Chen H, Gao L . 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorg Med Chem Lett. 2010; 20(20):6096-9. DOI: 10.1016/j.bmcl.2010.08.045. View

20.

Hetenyi C, van der Spoel D . Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett. 2006; 580(5):1447-50. DOI: 10.1016/j.febslet.2006.01.074. View